Antigen binding molecule specifically binding to CD19, CD20 and CD3, and pharmaceutical use thereof
By developing antigen-binding molecules that specifically bind to CD19, CD20, and CD3, the problem of drug resistance in the treatment of non-Hodgkin's lymphoma has been solved, improving treatment efficacy and cure rate, and adapting to tumor cells with different expression levels.
Patent Information
- Application Number
- PCT/CN2026/071543
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-01-10
- Filing Date
- 2026-01-09
- Publication Date
- 2026-07-16
AI Technical Summary
Current treatments for non-Hodgkin's lymphoma suffer from drug resistance, particularly relapses caused by the loss of CD19 or CD20 targets. Existing therapies are struggling to address this issue effectively, and there is room for improvement in treatment outcomes.
To develop an antigen-binding molecule that specifically binds to CD19, CD20, and CD3, comprising a first antigen-binding domain that specifically binds to CD19, a second antigen-binding domain that specifically binds to CD20, and a third antigen-binding domain that specifically binds to CD3, thereby enhancing the ability to respond to antigen loss or downregulation and improving the efficiency of tumor cell killing.
By simultaneously targeting CD19 and CD20, the treatment efficacy against drug-resistant non-Hodgkin lymphoma is enhanced, improving response and cure rates, and adapting to tumor cells with different expression levels.